Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02672865 · ClinicalTrials.gov registry record · Phase 1
Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer
A Phase 1 study, sponsored by Loma Linda University.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02672865 is a Phase 1 study that has completed, run by Loma Linda University. The registered enrollment target is 4 participants.
The verdict
NCT02672865, a Phase 1 study, has completed, sponsored by Loma Linda University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to determine safety and feasibility of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin and cisplatin in patients with locally advanced gastric cancer undergoing standard surgical resection. Patients will be treated with HIPEC using a single dose of mitomycin 15mg/m2 and cisplatin 50mg/m2 at 41-42 C for 90 minutes, during the definitive surgical resection for gastric cancer. HIPEC will be performed after resection but before anastomosis.
Interventions
- DRUG Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-02-02 |
| Est. Completion | 2018-10-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02672865
The ClinicalTrials.gov registry entry for NCT02672865 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loma Linda University, which has 237 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is the first listed.
NCT02672865 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02672865 about?
NCT02672865 is a clinical study titled "Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer". The purpose of this study is to determine safety and feasibility of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin and cisplatin in patients with locally advanced gastric cancer undergoing standard surgical resection. Patients will be treated with HIPEC using a single dose...
What is the current status of trial NCT02672865?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2016-02-02. Estimated completion is 2018-10-03.
What interventions are being tested in trial NCT02672865?
The interventions under investigation include: Hyperthermic Intraperitoneal Chemotherapy (HIPEC) (DRUG).
Who is sponsoring clinical trial NCT02672865?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.